Skip to content
TrialScanner

NCT04383938

Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies

Phase 1/Phase 2CompletedAPRELead

Registry record

Lead sponsor
Aprea Therapeutics
Conditions
Bladder Cancer; Gastric Cancer; Non Small Cell Lung Cancer; NSCLC; Urothelial Carcinoma
Primary completion
Apr 30, 2022Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT04383938 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT04383938: Phase 1/2 Study of APR-246... | TrialScanner